Novo Nordisk rises as Wegovy pill rolls out in Germany
Novo Nordisk rose about 0.5% to $45.545 after rolling out its Wegovy pill in Germany, bringing the oral weight-loss treatment to the EU’s largest pharmaceutical market.
Novo Nordisk NYSE:NVO, the diabetes and obesity-drug powerhouse, rose approximately 0.5% to $45.545 Tuesday after rolling out the Wegovy pill in Germany.
That puts Novo's oral weight-loss treatment into the European Union's largest pharmaceutical marketand gives Germany the EU's first taste of the…